+101.1%
HL vs GSK
+46.9%
+54.2%
-61.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -6.7% | -0.1% | -6.6% | -6.7% |
| 7D | -20.7% | -1.3% | -19.4% | -20.3% |
| 30D | -20.1% | +2.7% | -22.9% | -20.9% |
| 3M | -33.5% | +2.7% | -36.2% | -34.1% |
| 6M | -30.7% | +3.3% | -34.0% | -31.9% |
| YTD | -36.3% | +6.5% | -42.7% | -38.5% |
| 1Y | -16.2% | +10.7% | -26.9% | -20.4% |
| 3Y | +176.5% | +64.4% | +112.2% | +106.8% |
| 5Y | +101.1% | +46.7% | +54.4% | +42.6% |
| All | +101.1% | +46.9% | +54.2% | +42.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling